Be ready with more naloxone.¹,²

78% of opioid overdose reversals involved ≥2 doses of naloxone and 30% involved ≥3 doses, according to a 2021 survey of bystanders who have administered Narcan® (naloxone HCl) Nasal Spray 4 mg.³

KLOXXADO® has twice as much naloxone per dose (8 mg) as NARCAN® to counteract the risks of potent opioids.¹,²

Across KLOXXADO’s® two PK studies, adverse reactions were reported in two subjects for each of the following: abdominal pain, asthenia, dizziness, headache, nasal discomfort, and presyncope.¹

Who should carry KLOXXADO®?⁴

- Anyone taking high strength or otherwise chronic opioids (e.g., ≥ 50MME)
- Anyone taking opioids of any dose with a benzodiazepine
- Anyone with certain respiratory conditions taking opioids (e.g., COPD or sleep apnea)
- Anyone taking opioids of any dose with non-opioid substance use disorder or other mental health disorder
- Anyone with a history of overdose or substance use disorder, including PWUD and patients in recovery
- People likely to observe an overdose, particularly family, friends, or caregivers

$0 could reverse an opioid overdose⁵

KLOXXADO® is the first naloxone nasal spray to offer a savings card. Pay as little as $0 (up to $40 savings for eligible patients).⁵

To learn more about KLOXXADO® and download the savings card, please visit www.kloxxado.com.

INDICATION

KLOXXADO® is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression, for adult and pediatric patients. KLOXXADO® is intended for immediate administration as emergency therapy in settings where opioids may be present. KLOXXADO® is not a substitute for emergency medical care.

See full ISI on pages 2 and 3.
KLOXXADO® (naloxone HCl) Nasal Spray 8 mg Important Safety Information

CONTRAINDICATIONS
- Hypersensitivity to naloxone hydrochloride or to any of the other ingredients in KLOXXADO®

WARNINGS AND PRECAUTIONS
- **Risk of Recurrent Respiratory and Central Nervous System Depression**
  Seek emergency assistance immediately after administration of the first dose and keep the patient under continued surveillance. The duration of action of most opioids may exceed that of KLOXXADO®, resulting in a return of respiratory and/or central nervous system depression after an initial improvement in symptoms. Administer additional doses as necessary if the patient is not adequately responding or responds and then relapses back into respiratory depression.

- **Risk of Limited Efficacy With Partial Agonists or Mixed Agonist/Agonists**
  Reversal of respiratory depression by partial agonists or mixed agonist/antagonists may be incomplete. Larger or repeat doses of naloxone hydrochloride may be required.

- **Precipitation of Severe Opioid Withdrawal**
  Use in patients who are opioid-dependent may precipitate opioid withdrawal characterized by body aches, diarrhea, tachycardia, fever, runny nose, sneezing, piloerection, sweating, yawning, nausea or vomiting, nervousness, restlessness or irritability, shivering or trembling, abdominal cramps, weakness and increased blood pressure. In neonates, opioid withdrawal may be life-threatening if not recognized and properly treated and may include convulsion, excessive crying and hyperactive reflexes. Monitor the patient for the development of the signs and symptoms of opioid withdrawal. For more information about management of opioid withdrawal, see the full Prescribing Information.

  Abrupt reversal of opioid effects in persons who were physically dependent on opioids has precipitated an acute withdrawal syndrome. In some patients, there was aggressive behavior upon abrupt reversal of an opioid overdose.

  Abrupt postoperative reversal of opioid depression after using naloxone hydrochloride may result in nausea, vomiting, sweating, tremulousness, tachycardia, hypotension, hypertension, seizures, ventricular tachycardia and fibrillation, pulmonary edema and cardiac arrest. Death, coma and encephalopathy have been reported as sequelae of these events. These events have primarily occurred in patients who had pre-existing cardiovascular disorders or received other drugs that may have similar adverse cardiovascular effects. Monitor these patients closely in an appropriate healthcare setting.

References
ADVERSE REACTIONS
In two pharmacokinetic studies, a total of 47 healthy adult volunteers were exposed to a single dose of KLOXXADO®, one spray in one nostril.

• Adverse reactions were reported in two subjects for each of the following: abdominal pain, asthenia, dizziness, headache, nasal discomfort, and presyncope.
• Signs of nasal inflammation and nasal congestion were observed
• Serious adverse reactions reported: none

The following most frequently reported events (in decreasing frequency) have been identified primarily during post-approval use of naloxone hydrochloride: withdrawal syndrome, vomiting, nonresponsiveness to stimuli, drug ineffective, agitation, somnolence, and loss of consciousness.

USE IN SPECIFIC POPULATIONS

• Pregnancy
  Naloxone may precipitate opioid withdrawal in the pregnant woman and fetus. Careful monitoring is needed until the fetus and mother are stabilized.

• Infants
  In situations where the primary concern is for infants at risk for opioid overdose, consider the availability of alternate naloxone-containing products.

For more information, please see the full Prescribing Information and Patient Information, which you can find on our website at www.kloxxado.com.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit https://www.fda.gov/medwatch or call 1-800-FDA-1088.
Prescribe KLOXXADO® with opioids over 50 MME

Opioid dosing at or above 50 MME/day doubles the risk of overdose relative to <20 MME/day.6

HHS guidelines recommend naloxone with any “high dose” (≥50 MME* per day) opioid prescription.4

<table>
<thead>
<tr>
<th>50 MME/day for select opioids6</th>
</tr>
</thead>
<tbody>
<tr>
<td>Codeine</td>
</tr>
<tr>
<td>Fentanyl†</td>
</tr>
<tr>
<td>Hydrocodone</td>
</tr>
<tr>
<td>Hydromorphone</td>
</tr>
<tr>
<td>Methadone</td>
</tr>
<tr>
<td>Morphine</td>
</tr>
<tr>
<td>Oxycodone</td>
</tr>
<tr>
<td>Oxymorphone</td>
</tr>
</tbody>
</table>

*MME = “milligram morphine equivalent”
Used to enable a standardized comparison of opioid dose across products, often used as a gauge of the misuse or overdose potential of the amount of opioid that is being given at a particular time

†Fentanyl transdermal patch

IMPORTANT: There is no completely safe opioid dose, and this guide does not substitute for clinical judgment. Use caution when prescribing opioids at any dosage, and prescribe the lowest effective dose.

INDICATION
KLOXXADO® is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression, for adult and pediatric patients. KLOXXADO® is intended for immediate administration as emergency therapy in settings where opioids may be present. KLOXXADO® is not a substitute for emergency medical care.

See full ISI on pages 2 and 3.